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Objectives:Age-related changes in the hemostatic system result in variation in response to anticoagulants and co-
agulation assays over childhood. This studyused in vitromethods to determine i) optimum coagulation assays for
dabigatran in children and ii) anticoagulant effect of dabigatran across pediatric age groups.
Materials and Methods: Pooled plasma samples from healthy children aged 0 to b1, 1 to b5, 5 to b10, 10 to
b17 years and adults were spiked with increasing concentrations of dabigatran and the effect was assessed in
ﬁve coagulation assays. The samples were also assessed for overall hemostasis potential using a ﬁbrin clot forma-
tion and lysis assay.
Results: In all ﬁve coagulation assays, there were no differences in responses to dabigatran over all pediatric age
groups. The international normalized ratiowas the least sensitivemeasure. Activated partial thromboplastin time
showed moderate sensitivity and a nonlinear response curve. Thrombin time (TT), dilute TT (dTT) and ecarin
clotting time were linearly correlated with dabigatran concentrations; however, the ecarin time and TT were
overly sensitive. In the overall hemostasis potential assay, increasing dabigatran concentrations delayed the ini-
tiation of clot formation and reduced the time to 50% clot lysis. The responses to initiation of clot formation and
clot lysis were consistent across all pediatric groups and comparable to responses in adults.
Conclusion: The dTT is the most suitable assay for measuring dabigatran concentrations in children. Fibrin clot
generation and lysis assay responses to dabigatran in children over all ages were consistent and comparable to
those of adults.© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Dabigatran etexilate is the orally available prodrug of the direct
thrombin inhibitor, dabigatran. It is currently used in adults for preven-
tion of stroke in patients with nonvalvular atrial ﬁbrillation [1], for pre-
vention of venous thromboembolic events after total hip or knee
replacement [2–4], for treatment of deep venous thrombosis (DVT)
and pulmonary embolism (PE) after use of a parenteral anticoagulant
for 5–10 days, and to reduce the risk of recurrence of DVT and PE inime; dTT, dilute thrombin time;
INR, international normalized
ary embolism; PT, prothrombin
is;UFH,unfractionatedheparin;
ch Centre, University of Alberta,
1 7804923550.
. This is an open access article underpatients who have been previously treated [5,6]. Dabigatran is currently
not approved for use in children (aged b18 years). In comparison to
adults, children are at relatively low risk for DVT; however, the preva-
lence of DVT in children is increasing [7]. Children with risk factors
such as central venous catheters, hospitalization, infection/sepsis, or
cardiac disorders are susceptible to DVT and require anticoagulant ther-
apy [8–10].
The most commonly used anticoagulants in children are low-
molecular-weight heparins (LMWHs), unfractionated heparin (UFH),
and vitamin K antagonists (VKAs). These conventional anticoagulants
have general drawbacks, such as variable pharmacokinetic and antico-
agulant effects that necessitate routinemonitoring and dose adjustment
or a requirement for parenteral administration [11–13]. Factors such as
parenteral drug administration, vascular access for monitoring, and die-
tary vitamin K content complicate use of these drugs in children [8].
There are well-described physiological, age-related variations in the
hemostatic system occurring from birth and throughout childhood that
profoundly impact anticoagulation in children [14–16]. Differences in
the hemostatic system result in variation in response to anticoagulants
throughout childhood. In addition, coagulation assays that werethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sponse to anticoagulation in children. Indeed, the in vitro response of
standard clotting assays to UFH and the ex vivo response towarfarin dif-
fer when performed in plasma from children compared with plasma
from adults [17–20].
Dabigatran etexilate acts independently of endogenous antithrombin
levels, and has the advantage of oral administration, dose-proportional
pharmacokinetics and pharmacodynamics, and fewdrug interactions, ob-
viating routine coagulationmonitoring in adults [21]. Several assays have
been evaluated for the qualitative or quantitative determination of
dabigatran in plasma [22]. To date, no study has assessed dabigatran in
pediatric patients. Determining the optimum coagulation assay for
assessing plasma levels in children and characterizing the anticoagulant
response to dabigatran across different age groups is important. We
therefore assessed the in vitro effect of dabigatran in plasma of children
of differing ages, compared with adults, using standard clotting assays.
In addition, we determined the anticoagulant response to dabigatran
over childhood using an overall hemostasis potential assay that assesses
the capacity for ﬁbrin clot formation and ﬁbrin clot lysis.
Methods
Plasma Samples
Venous blood samples were pooled from at least 9 to 11 subjects in
each pediatric age group and 20 adults. The protocol was approved by
University of Alberta Ethics ReviewBoard. Normal healthy children hav-
ing clinical bloodwork done for routine elective surgery at Stollery Chil-
dren’s Hospital, Edmonton, Canadawere eligible for inclusion. Children/
legal guardians gave written assent/consent.
Platelet-poor plasma was prepared from citrated whole blood by
centrifugation and was stored at –80 °C.
Dabigatran
Dabigatran (Boehringer Ingelheim, Biberach, Germany) dissolved in
0.1 N hydrochloric acid to 10 mg/ml was frozen in single-use aliquots
(–80 °C). These were diluted for use with HEPES-buffered saline
(pH 7.05) to three stock concentrations. Pooled platelet-poor plasma
from each age group was divided into ﬁve aliquots and dabigatran (or
vehicle) was added: ﬁnal concentrations 0, 50, 250, and 450 ng/ml.
Coagulation Assays
Assays were performed for each dabigatran concentration using an
automated coagulation analyzer (ACL 300+, Instrumentation Laborato-
ry, Milan, Italy) following standard procedures [23].
Thrombin Time (TT)
Sample plasma and reagent (1.5 National Institutes of Health [NIH]
units/ml human thrombin [Stago, Toronto, Canada] containing calcium)
were prewarmed (37 °C, 180 seconds) and mixed.
Dilute Thrombin Time (dTT)
Sample plasma, diluted 1:8with saline, was incubatedwith standard
plasma pool (Hemoclot Thrombin Inhibitor Kit, Hyphen Biomed,
Neuville-sur-Oise, France) (37 °C, 60 seconds). Prewarmed human cal-
cium thrombin from the kit was added [24].
Ecarin Clotting Time (ECT)
Plasma was mixed with ecarin reagent containing calcium (Sigma-
Aldrich E0504, Oakland, Canada) at a ﬁnal concentration of 2 units/ml
after prewarming (37 °C, 120 seconds) [25].Activated Partial Thromboplastin Time (aPTT)
Plasma was incubated (37 °C, 270 seconds) with SynthaSil (Instru-
mentation Laboratory, Bedford, MA, USA), then prewarmed calcium
(0.2 M) was added.Prothrombin Time (PT)
Prewarmed (37 °C, 180 seconds) plasma and Hemoliance
RecombiPlasTin (Instrumentation Laboratory) containing recombi-
nant human tissue factor and calcium were mixed. PT values were
used to estimate international normalized ratio (INR; ratio of test to
control PT).Overall Hemostasis Potential Assay
The assay [26] was performed in microtiter plates (Corning Inc,
Corning, NY, USA). Change in turbidity at 405 nm was followed
using a SpectraMax microplate reader (Molecular Devices, Sunny-
vale, CA, USA). Assays were initiated by adding 60-μl aliquots of plas-
ma sample (35 μl) in 0.02 M HEPES/0.15 M sodium chloride/0.01%
Tween 80 (25 μl) to 40-μl aliquots, containing 5 mM calcium
chloride, 1/800 dilution tissue factor ﬁnal concentration 2.5 pM,
(RecombiPlasTin, Instrumentation Laboratory, Richmond Hill, ON,
Canada), 15 μM L-α-phosphatidylcholine/L-α-phosphatidylethanol-
amine/L-α-phosphatidylserine vesicles (Avanti Polar Lipids, Alabas-
ter, AL, USA), and 3 nM tissue plasminogen activator (Alteplase,
Cedarlane Laboratories, Burlington, Canada).
Lag time to initiation of clot formation is the time from the initial read-
ing to an increase in absorbance from baseline. Time to 50% of clot lysis
(t½ clot lysis) is the interval from maximum absorbance at 405 nm to
a 50% reduction in turbidity.Statistical Analyses
The coagulation assays and overall hemostasis potential assay pa-
rameters were compared between age groups and dabigatran concen-
trations using the Kruskal-Wallis test; P b 0.05 considered signiﬁcant.Results
Patients
Median ages of the pediatric groups were: 0 to b1 year, 5 months
(n = 9); 1 to b5 years, 2 years (n = 9); 5 to b10 years, 6 years (n =
11); 10 to b17 years, 12 years (n = 12). The adult group consisted of
20 subjects.Coagulation Assays
There was no difference in response to increasing dabigatran con-
centrations in plasma from each of the pediatric age groups in the ﬁve
coagulation assays. However, the clotting times, with increasing con-
centration of dabigatran, for the aPTT, ECT, and TT were longer in chil-
dren compared with adults. Baseline aPTT and ECT were signiﬁcantly
longer across the pediatric groups compared with the adult group.
Therefore, the aPTT and ECT were calculated as a ratio of the test to
the baseline clotting time. These ratios of aPTT and ECT response to in-
creasing dabigatran concentrations were similar in adults and children.
Baseline TT did not differ signiﬁcantly between adult and pediatric
groups. Compared with the adult group, the pediatric groups showed
increased sensitivity to dabigatran using the TT. The dTT showed no sig-
niﬁcant difference at baseline between children and adults. The re-
sponse to increasing dabigatran concentrations was similar in the
pediatric and adult plasma. However, there were differences in the sen-
sitivity and linearity among assays (Fig. 1).
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Fig. 1. Relationship between dabigatran concentration and response using ﬁve different coagulation assays in plasma of children and adults.
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The aPTT was moderately sensitive to increasing dabigatran con-
centrations with an ~3-fold prolongation over baseline at the
highest concentration, though the response was not linear. The pe-
diatric groups had a prolonged baseline aPTT; however, when base-
line was corrected for, by calculating the data as a ratio to baseline,
it was apparent that there was no difference in the sensitivity to
dabigatran when compared with the adult plasma (data not
shown). The aPTT results were reproducible at dabigatran concen-
trations up to 450 ng/ml (Fig. 1A).ECT
The ECT assay showed an extremely sensitive linear response to
dabigatran concentrations in all pediatric groups. ECT was consistent
over all pediatric age groups, but signiﬁcantly different from the adult
group. The baseline ECTs were prolonged compared with adults; when
baseline was corrected for by calculating as a ratio over baseline, there
was no difference in the sensitivity to dabigatran when compared with
adults (data not shown). Clotting times were ~6.5-fold over baseline at
450 ng/ml dabigatran (Fig. 1B). Reproducibility of the assay was poor at
increased dabigatran concentrations.
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The PT values represented as an INR were relatively insensitive, but
displayed a linear response to increasing dabigatran concentrations. The
pediatric groups displayed comparable results to the adults. Even with
concentrations up to 450 ng/ml, a 2-fold prolongation over baseline
was not achieved (Fig. 1C). Reproducibility of assay measurements
was good.
TT
The TT assay was extremely sensitive to increasing dabigatran
concentrations in pediatric and adult plasma (Fig. 1D). Mean baseline
TT was 18.9 to 19.5 seconds across all ages. There were no differences
in response to dabigatran across pediatric groups. The sensitivity across
pediatric groupswas somewhat increased comparedwith adult plasma,
with an ~15- to 18-fold prolongation of baseline at 450 ng/ml in pediat-
ric plasma, versus a 13.1-fold elevation in adult plasma. The assay was
not reproducible for prolonged clotting times.
dTT
The dTTwas sensitive to increasing dabigatran concentrations in pe-
diatric plasma and displayed a linear relationship between clotting time
and dabigatran concentration. The results were similar between
pediatric and adult groups, with a ~3-fold prolongation over baseline
measured at the highest dabigatran concentration of 450 ng/ml in pedi-
atric plasma and a 3.36-fold prolongation in adult plasma (Fig. 1E). The
dTT was very reproducible between measurements.
Overall Hemostasis Potential (Fig. 2)
In children and adults, increasing concentrations of dabigatran in-
creased the lag time to initiation of clot formation, and decreased the
t½ clot lysis time, in a linear fashion. The proﬁle of the overall hemostasis
potential assaywith the highest concentration of dabigatran, 450 ng/ml,
was slightly different than the other curves, even though the lag time
was further prolonged and the lysis time reduced. This reﬂects an arti-
fact of the system, since the turbidity of the plasma is being measuredA
B
Fig. 2. Effect of increasing concentrations of dabigatran on clot formation and lysis (hemo-
static capacity assay) in plasma of children aged 1 to b5 years (A) and adults (B).and at this concentration of dabigatran clot formation is no longer nor-
mal, but the clots that form are very soft, do not retract and thus create a
more turbid effect even though there is not more clot formation. Thus it
represents a type of ﬁbrin monomer/short chain “suspension” which
has a higher absorbance than clear control.
Lag Time to Initiation of Clot Formation
At baseline, there was a signiﬁcant difference in lag time between all
pediatric groups and adults, with children having a shorter lag time to
clot initiation (P = 0.005). However, there were no differences in lag
time across the pediatric age groups (P = 0.64). Ratio data were used
to correct for baseline differences. Across the pediatric groups, there
was no difference in the ratios at any dabigatran concentration: 50
ng/ml, P= 0.12; 250 ng/ml, P= 0.08; 450 ng/ml, P= 0.07. Comparing
all pediatric groups versus the adult group, there was a statistically sig-
niﬁcant decrease in response at lower dabigatran concentrations (50
ng/ml, P b 0.001; 250 ng/ml, P = 0.001), but no difference at 450
ng/ml (P = 0.18). The variations in response to clot initiation were
minor, with 6% to 7% difference between the adult and pediatric plasma
at lower dabigatran concentrations.
Time to 50% of Clot Lysis
At baseline, there was a signiﬁcant difference between all pediatric
groups and adults, with the pediatric groups having a slightly longer
t½ lysis time (P b 0.001). However, there was no difference in t½ lysis
time across pediatric age groups (P=0.23). Correcting for baseline dif-
ferences, there was no signiﬁcant difference among all pediatric age
groups when comparing the ratio data over all dabigatran concentra-
tions. Also, no signiﬁcant difference was seen in the t½ clot lysis ratio
comparing adult and children over all age groups and all dabigatran
concentrations.
Discussion
Novel oral anticoagulants such as dabigatran etexilate are used in
adults inﬁxed doseswithout routine anticoagulationmonitoring. In cer-
tain situations, such as bleeding into critical organs, a suspected over-
dose, or emergency surgery, the anticoagulant status may need to be
determined using a suitable assay. In addition, a reliable assay is useful
for determining plasma drug concentrations in clinical trials, including
pharmacokinetic studies. In children, the most critical determinant of
anticoagulant dosing is age, because age has a profound effect on drug
clearance with younger children requiring increased doses [27,28].
Therefore, monitoring of novel anticoagulants may be necessary in chil-
dren, as the dosingmay change in relation to the age of the child during
treatment, as is the case with warfarin and heparin. The objective of the
current study was to determine coagulation assay response over child-
hood at ﬁxed concentrations of dabigatran using various laboratory as-
says as compared with adults.
The range of dabigatran concentrations tested represents the antici-
pated therapeutically relevant range and above. For example, popula-
tion pharmacokinetic modelling based on adult patients with atrial
ﬁbrillation provides an estimated steady-state peak plasma dabigatran
concentration of 184 ng/ml (5th and 95th percentiles 64-443 ng/ml)
and a trough concentration of 90 ng/ml (31–255 ng/ml, respectively)
after 150 mg twice-daily dosing with dabigatran etexilate. A 220 mg
once-daily regimen results in a lower trough level of 37 ng/ml (10–96
ng/ml, respectively) [22].
The assays used in our study have been evaluated previously in adult
plasma samples and results of the current study support the previous
key ﬁndings [22]. The least sensitive measure of dabigatran was the
INR. The aPTT showedmoderate sensitivity and a consistent but nonlin-
ear concentration–response curve. The dTT, TT, and ECT were linearly
and sensitively correlated with plasma dabigatran concentrations.
However, the TT and ECT were too sensitive, resulting in extremely
prolonged clotting times – negatively impacting the reproducibility of
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assay for measuring dabigatran concentrations within and in excess of
the therapeutic range in children, which is in agreement with ﬁndings
in adults [22]. The dTT performed consistently across all age groups
and the clotting times were similar to (or slightly shorter than) those
in adult plasma. Furthermore, the dTT showed good reproducibility.
The assay is commercially available with dabigatran standards for cali-
bration [22].
Within each of the 5 assays, there were no remarkable differences
among the coagulation assay responses to dabigatran from the different
pediatric groups. In these assays, the pediatric plasma pools had slightly
longer clotting times than the adult pool in control and dabigatran-
spiked samples, possibly reﬂecting differences in the hemostatic system
of healthy children [14]. Signiﬁcant age-related differences in the effects
on standard coagulation assays in vitro have been reported previously
for several anticoagulants. For example, at each concentration of UFH
tested, the aPTTwas longer and anti-IIa activitywas increased in plasma
from children compared with adults. In addition, the difference in effect
from that in adult plasma was more marked in the younger children
(ages b1 year and 1 to b5 years) than in the older children [18]. A sim-
ilar pattern of aPTT responses has been reported for danaparoid (a low-
molecular-weight heparinoid) and lepirudin (a direct thrombin inhibi-
tor) [19]. The ECT response to lepirudin was lower (shorter coagulation
times) in children compared with adults [19]. Differing effects on
thrombin generation assays between children and adults have also
been reported for UFH, LMWH, and warfarin [17,20]. In contrast, no
age-related effect was seen on the TT assay with LMWH [29]; on aPTT
or PT with rivaroxaban (a direct factor Xa inhibitor) [30]; on anti-Xa as-
says with LMWH [29], fondaparinux (an antithrombin-dependent fac-
tor Xa inhibitor) [19], rivaroxaban [30], or danaparoid [19]; or on an
anti-IIa assay with lepirudin [19].
The overall hemostasis potential assay quantiﬁes the plasma
capacity to both generate a ﬁbrin clot and lyse the ﬁbrin clot, allowing
assessment of coagulant and ﬁbrinolytic capacity in one system; this is
more comprehensive than thrombin generation assays, which only
assess the capacity to generate thrombin [26]. The overall hemostasis
potential assay uses plasma, offering distinct advantages over the
thromboelastography tests, which require fresh whole blood and do
not allow for pooling of samples. A similar assay to the overall hemosta-
sis potential assay, the clot formation and lysis assay, has been used in
pediatric patients to assess coagulation and ﬁbrinolytic capacity in chil-
drenwithDVT [31]. In vitro studies in adults have assessed the anticoag-
ulant effect of dabigatran using the overall hemostasis potential assay
[32,33]. Results from both studies indicated that dabigatran decreased
ﬁbrin formation and enhanced ﬁbrinolysis. Data from the current
study using adult plasma demonstrated that the response in the overall
hemostasis potential assay to increasing dabigatran concentrations for
both the clot generation and clot lysiswere in agreementwith previous-
ly published studies [32,33]. In terms of clot generation, therewas an in-
crease in the lag time to clot initiation with increasing dabigatran
concentrations, reﬂecting the thrombin inhibition by the anticoagulant.
Regarding the capacity for ﬁbrin clot lysis, therewas a decrease in the t½
clot lysis time, reﬂecting dabigatran’s ability to enhance clot susceptibil-
ity to ﬁbrinolysis. When corrected for baseline, the response to
dabigatran was comparable in children and adults. Of note, the antico-
agulant response was identical in children across all ages, which is an
important observation for this drug in pediatrics: all other current anti-
coagulants show a differing response in children compared with adults
[17,20]. The fact that the response to dabigatran in pediatric plasma is
relatively consistent with adult plasma is promising, possibly indicating
that the clinical response is comparable to that in adults. Also, the re-
sponse is consistent across all pediatric ages, suggesting that age-
related differences in the hemostatic system do not alter the response
to dabigatran. While the in vitro response to dabigatran does not vary
over age, the current study was not designed to assess dose require-
ments over age, which is being assessed in properly designed dose-ﬁnding Phase II pharmacokinetic/pharmacodynamic studies. Finally,
the efﬁcacy and safety of dabigatran in children of all ages must be
assessed in adequately powered clinical trials.
Due to restrictions on acceptable volumes of blood from children for
research purposes there was insufﬁcient sample to do subjects individ-
ually. Therefore, one of the limitations of the study was that testing was
done on spiked pooled plasma from the various age groups rather than
individual plasmas spiked with dabigatran. However, this approach is
reasonable and a relatively common approach to such studies in
children.
Dabigatran etexilate is currently being assessed for safety and efﬁca-
cy in children in carefully designed clinical trials. A total of six clinical
trials, four Phase II and two Phase III have been undertaken and one
Phase II trial has been completed (http://clinicaltrials.gov). Although it
is hoped that dabigatran etexilate could ultimately be used in children
without routine monitoring (as in adults), the availability of a simple
assay that provides consistent results across age groups is invaluable
in helping to identify suitable doses during the pediatric clinical devel-
opment process.
In conclusion, the coagulation assay response to dabigatran for of all
tests was similar in pediatric plasma compared with adult plasma. The
ECT and TT were more variable between adult and pediatric plasma,
particularly as dabigatran concentrations increased, reﬂecting inaccura-
cies in reproducibility of these assays as the clotting times become
prolonged. From a practical perspective, the dTT is an appropriate tool
for measuring dabigatran concentrations in children, as also holds true
in adults [22]. The dTT performed consistently across all age groups,
and showed good reproducibility between repeat measurements and
appropriate sensitivity and linearity of response within and above the
therapeutic range. In addition, the anticoagulant response to dabigatran,
as assessed by the capacity to generate a ﬁbrin clot, is consistent over
childhood and comparable to the adult response. Finally, the increased
susceptibility to ﬁbrin clot lysis associated with dabigatran is consistent
over childhood and similar to that in adults. However, it is important to
note that the results of the current study are preliminary pending con-
ﬁrmation in vivo in pediatric patients receiving dabigatran.
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